|
Destiny Pharma PLC - clinical-stage biotechnology company based in Brighton, England - Receives positive feedback from European Medicines Agency on phase 3 programme for XF-73 nasal gel. XF-73 is being developed to treat surgical staphylococcal infections. "This positive advice is welcomed by the company as it identifies a clear route through European approval of XF-73 Nasal gel as a ground-breaking hospital infection prevention product," Destiny adds.
Current stock price: 91.00 pence
12-month change: down 22%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
